June 11, 2019
Orthotopic or Subcutaneous Tumor Homograft Models?
When should you use either subcutaneous or orthotopic pancreatic cancer tumor homografts, and where do they best support your drug discovery workflow?
LEARN MORE
May 30, 2019
Key Differences between hPBMC and hCD34 Humanized Mouse Models
Learn more about the different human immune cell populations in PBMC and HSC-humanized mouse models, to help select the ...
LEARN MORE
May 7, 2019
Combination Therapies and Tumor Homograft Models
Learn more about using tumor homograft models to assess oncology combination regimens, including immunotherapies.
LEARN MORE
April 25, 2019
Large-Scale Immunotherapy Screening: How and Why?
Learn more about the need for large-scale cancer immunotherapy screens and the different immunocompetent models ...
LEARN MORE
April 16, 2019
5 Criteria for Choosing a Contract Research Organization
Contract research organizations (CROs) vary in capability, quality, experience, cost, and ease of collaboration. Weigh ...
LEARN MORE
April 3, 2019
New Analysis, Model ID, and Modeling Technologies at AACR 2019
In Atlanta this week we’re presenting data on our new analysis platforms and preclinical technologies. This post recaps ...
LEARN MORE
April 2, 2019
Syngeneic and Tumor Homograft Immuno-Oncology Models at AACR 2019
Recap all our AACR presentations on murine models including bioluminescent orthotopic syngeneic models, syngeneic model research into immune cell lineage impact on anti-PD-1 response, and prostate cancer tumor homograft models.
LEARN MORE
April 1, 2019
Humanized Model Update at AACR 2019
Review all the new data on our humanized target models for human-specific CD40 and combination regimen assessment, and ...
LEARN MORE
April 1, 2019
AACR19 Analysis: PDX and PDX-Derived Organoid Models
Review all the new data on patient-derived xenograft (PDX) models we’re presenting at AACR 2019 this week, including ...
LEARN MORE
March 29, 2019
Tumor Antigen Targets for Personalized Adoptive T Cell Therapies
Discover the types of tumor antigens available for T cell therapies, including tumor-specific antigens, ...
LEARN MORE
March 26, 2019
Patient-Derived Organoids (PDOs) for Personalized Cancer Research
Learn more about patient-derived organoids, a unique ex vivo tool enabling personalized cancer research for improved treatment of metastatic disease.
LEARN MORE
March 14, 2019
LAG3: A Promising New Cancer Immunotherapy Target
As we continue our discussion of the immune revolution in cancer therapy, we look at the benefits of targeting LAG3, an ...
LEARN MORE
March 7, 2019
Genetic Abnormality Spectrum in Hematologic Cancers
What have we learned about the genetics of hematological cancers, and how can that be modelled for research and drug ...
LEARN MORE
March 6, 2019
Using Genetic Features to ID and QC Murine Tumor Models
Learn how unique genetic events can be used to generate a “genetic fingerprint” to ID and QC murine tumor models.
LEARN MORE
March 5, 2019
Recognizing and Profiling T Cell Receptors
Learn more about T cell receptors in personalized T cell therapy, including TCR diversity, repertoire, and how TCR are ...
LEARN MORE
